Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine

Vaccine

Volumn 21, Issue 32, 2003, Pages 4668-4676

  Santos, Wania Renata ^a   Aguiar, Ivan Augusto ^a   De Souza, Edilma Paraguai ^a   De Lima, Valéria M F ^b   Palatnik, Marcos ^a   Palatnik de Sousa, Clarisa Beatriz ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

FML vaccine; Immunoprophylaxis; Immunotherapy; Kala azar; Saponin; Vaccination; Visceral leishmaniasis

Indexed keywords

ANTIPROTOZOAL AGENT; CYTOKINE; FUCOSE MANNOSE LIGAND VACCINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; EXPERIMENTAL MODEL; FEMALE; HUMORAL IMMUNITY; HYPERSENSITIVITY; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; INFECTION CONTROL; LEISHMANIA DONOVANI; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN BLOOD LEVEL; VISCERAL LEISHMANIASIS;

EID: 0242320930     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00527-9     Document Type: Article

References (50)

1. Schmunis GA, López Antuñano FJ. World-wide importance of parasites. In: Colier L, Balows A, Sussmanm M, editors. Microbial Infections. Topley & Wilson; 1997. p. 19-38.
2. Convit J., Castellano P.L., Rondon A., Penardi M.E., Ulrich M., Castes M.et al. Immunotherapy versus chemoterapy in localized cutaneous leishmaniasis. Lancet. 1:1987;401-414.
3. Mayrink W., Magalhães P.A., Michalick M.S.M., Costa C.A., Lima A.O., Melo M.N.et al. Immunotherapy as treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Parasitologia. 34:1992;159-165.
4. Toledo V.P., Mayrink W., Gollob K.J., Oliveira M.A., Costa C.A., Genaro O.et al. Immunochemotherapy of American cutaneous leishmaniasis: immunologycal aspects before and after treatment. Mem. Inst. Oswaldo Cruz. 96:2002;89-98.
5. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies. Am. J. Trop Med Hyg. 52:1995;287-292.
6. Lanotte G., Rioux J.Á., Pereires J., Vollhardt Y. Ecologie des leishmanioses dans le sud de la France. 10. Les formes évolutives de la leishmaniose viscérale canine. Elaboration d'une typologie bio-clinique à finalité épidémiologique. Ann Parasitologie. 54:1979;277-295.
7. Reiter I.V., Kretzschmar A., Boch J., Krampitz H. Zur leishmaniose des hundes. Infektionsverlauf, diagnose un therapieversuche nach exp. Infection vom Beagles mit Leishmania donovani (st. Kalkutta). Berl Münc Tierärztl Wschr. 98:1985;40-44.
8. Gradoni L., Maroli M., Gramiccia M., Mancianti F. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med. Vet. Entomol. 1:1987;339-342.
9. Mancianti M., Gramiccia M., Gradoni L., Pieri S. Studies on canine leishmaniasis control. I Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans R Soc Soc Trop Med Hyg. 82:1988;566-567.
10. Ranque J., Ranque M., Cabassu J., Cabassu H. Le diagnostic précoce de la leishmaniose canine par la ponction ganglionnaire. Reflexions à propor de soixante examens positifs obtenus en dix mois dans la région Marsellaise. Bull Acad Nat Med. 132:1948;339-340.
11. Marzochi M.C.A., Coutinho S.G., Souza W.J.S., Toledo L.M., Grimaldi G. Jr., Momen H.et al. Canine visceral leishmaniasis in Rio de Janeiro, Brazil. Clinical, parasitological, therapeutical and epidemiological findings (1977-1983). Mem Inst Osw Cruz. 80:1985;349-357.
12. Alvar J., Molina R., San Andrés M., Tesouro M., Nieto J., Vitutia M.et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88:1994;371-378.
13. Oliva G., Gradoni L., Cortese L., Orsini S., Ciaramella P., Scalone A.et al. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Ann Trop Med Parasitol. 92:1998;165-171.
14. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribanez M.A., Alvar J.et al. Canine leishmaniasis transmission: higher infectivity among naturally infected dogs to sandflies is associated with lower proportions of T helper cells. Res. Vet. Sci. 69:2000;249-253.
15. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribáñ ez M.A., Castillo J.Á. Evaluation of a speciific immunochemistry for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol. 88:2002;13-20.
16. Palatnik C.B., Borojevic R., Previato J.O., Mendonça-Previato L. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect Immun. 57:1989;754-763.
17. Palatnik de Sousa C.B., Dutra H.S., Borojevic R. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML). Acta Trop. 53:1993;59-72.
18. Palatnik C.B., Previato J.O., Mendonça-Previato L., Borojevic R. A new approach to phylogeny of Leishmania: species-specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasitol Res. 76:1990;289-293.
19. Palatnik de Sousa C.B., Paraguai de Souza E., Gomes E.M., Borojevic R. Experimental murine Leishmania donovani infection: immunoprotection by the fucose mannose ligand (FML). Braz J. Med Biol Res. 27:1994;547-551.
20. Santos W.R., Paraguai de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model. Vaccine. 17:1999;2554-2561.
21. Santos W.R., de Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine. 21:2002;30-43.
22. Palatnik de Sousa C.B., Gomes E.M., Paraguai de Souza E., Luz K., Palatnik M., Borojevic R. Leishmania donovani: titration of antibodies to the fucose mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans Roy Soc Trop Med Hyg. 89:1995;390-393.
23. Borja Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O.et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am. J. Trop Med Hyg. 61:1999;296-301.
24. Palatnik de Sousa C.B., Gomes E.M., Paraguai de Souza E., Santos W.R., Macedo S.R., Medeiros L.V.et al. The FML (fucose mannose ligand) of Leishmania donovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against human Kala-azar. Rev Soc Bras Med Trop. 29:1996;153-163.
25. Paraguai de Souza E., Bernardo R.R., Palatnik M., Palatnik de Sousa C.B. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine. 19(23-24):2001;3104- 3115.
26. Santana D.M., Paraguai de Souza E., Borja-Cabrera G.P., Sturm N.R., Palatnik de Sousa C.B., Campbell D.A. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis. Mol Biochem Parasitol. 120:2002;315-319.
27. Bernardo R.R., Palatnik de Sousa C.B., Parente J.P. N-linked oligossacharide structures of the FML antigen of Leishmania (L.) donovani. Mem Inst Oswaldo Cruz. 93(SII):1998;179.
28. Borja-Cabrera GP. Análise do potencial diagnóstico, prognóstico e imunoprotetor do antígeno FML (Ligante de Fucose Manose) de Leishmania (L.) donovani, no calazar canino experimental e de área endêmica. PhD Thesis. Department of Experimental Pathology. Federal Fluminense University; 2000. p. 81-98.
29. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M.et al. A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 19:2001;1068-1081.
30. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M.et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 20(27-28):2002;3277-3284.
31. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., Borojevic R. The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-Azar. Ciência e Cultura (J Braz Assoc Adv Sci). 46:1994;290-296.
32. Schetters T.P.M., Kleuskens J., Scholtes N., Bos H.J. Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture. Parasite Immunol. 14:1992;295-305.
33. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1 and Th2 derived cytokines does not determine the genetically controlled or vaccined induced rate of cure in murine visceral leishmanisis. J. Immunol. 146:1991;2763-2770.
34. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol Methods. 65:1983;55-63.
35. WHO. Control of the leishmaniases. World Heatlth Organization - Technical Report Series 793; 1990.
36. Olliaro P.L., Bryceson A.D.M. Practical progress and new drugs for changing patterns of Leishmaniasis. Parasitol. Today. 9:1993;323-328.
37. Pal S., Mandal A., Duttagupta S. Studies on stibanate resistant Leishmania donovani isolate of Indian origin. Indian J. Exp. Biol. 39:2001;249-254.
38. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 6:2001;849-854.
39. Koff A.B., Rosen T. Treatment of cutaneous leishmaniasis. J. Am. Acad Dermatol. 31:1994;693-708.
40. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Inf Dis. 24:1997;684-703.
41. Akendengue B., Ngou-Milama E., Laurens A., Hocquemiller R. Recent advances in the fight against leishmaniasis with natural products. Parasite. 6:1999;3-8.
42. Handman E., Noormohammadi A.H., Curtis J.M., Baldwin T., Sjölander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine. 18:2000;3011-3017.
43. Mukhopadhyay S., Sem P., Bhattacharyya S., Majumdar S., Roy S. Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. Vaccine. 17:1999;291-300.
44. Bourdoiseau G., Bonnefont C., Hoareau E., Boehringer C., Stolle T., Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunopathol. 59:1997;21-30.
45. Moreno J., Nieto J., Chamizo C., Gonzalez F., Blanco F., Barker F.et al. The immune response and PBMC subsets in canine visceral leishmaniasis before and after chemotherapy. Vet Immunopathol. 30:1999;181-195.
46. Mendes CO, Paraguai de Souza E, Borja-Cabrera GP, Melo Batista LM, Santos MA, Parra LE, et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine 2003;21:2589-97.
47. Gomes N.A., Barreto-de-Souza V., Dos Reis G.A. Early in vitro priming of distinct Th cell subsets determines polarized growth of visceralizing leishmania in macrophages. Int. Immunol. 12:2000;1227-1233.
48. Bradley DJ. Genetics of susceptibility and host resistance in the vertebrate host. In: The Leishmaniasis, vol. 2. London: Academic Press; 1987. p. 551-81.
49. Marciani D.J., Pathak A.K., Reynolds R.C., Seitz L., May R.D. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int Immunopharmacol. 1:2001;813-818.
50. Cruz Mendes A, Borja Cabrera GP, Paraguai de Souza E, Santos WR, Gomes EM, Palatnik de Sousa CB. Immunotheraphy against canine kala-azar with the FML antigen of L. (L.) donovani and the QuilA saponin. In: Proceedings of Fifthe Meeting on Applied Research on Leishmaniasis (Abs.). Uberaba, MG, Brasil; 2001. p. 80-81.